Related Experiment Video
Updated: Jun 12, 2026

Simple and Fast Rolling Circle Amplification-Based Detection of Topoisomerase 1 Activity in Crude Biological Samples
Published on: December 2, 2022
DNA topoisomerases and their poisoning by anticancer and antibacterial drugs
Yves Pommier1, Elisabetta Leo, HongLiang Zhang
1Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4255, USA. pommier@nih.gov
Abstract:
DNA topoisomerases are the targets of important anticancer and antibacterial drugs. Camptothecins and novel noncamptothecins in clinical development (indenoisoquinolines and ARC-111) target eukaryotic type IB topoisomerases (Top1), whereas human type IIA topoisomerases (Top2alpha and Top2beta) are the targets of the widely used anticancer agents etoposide, anthracyclines (doxorubicin, daunorubicin), and mitoxantrone. Bacterial type II topoisomerases (gyrase and Topo IV) are the targets of quinolones and aminocoumarin antibiotics. This review focuses on the molecular and biochemical characteristics of topoisomerases and their inhibitors. We also discuss the common mechanism of action of topoisomerase poisons by interfacial inhibition and trapping of topoisomerase cleavage complexes.
Insights
DNA topoisomerases are crucial drug targets for cancer and bacterial infections. Inhibitors like camptothecins and quinolones work by trapping enzyme-DNA complexes, offering therapeutic potential.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- DNA topoisomerases are essential enzymes involved in DNA replication, transcription, and repair.
- These enzymes are validated targets for numerous anticancer and antibacterial drugs.
- Existing drugs target both eukaryotic (Top1, Top2) and bacterial (gyrase, Topo IV) topoisomerases.
Purpose of the Study:
- To review the molecular and biochemical properties of topoisomerases.
- To discuss the characteristics of various topoisomerase inhibitors.
- To elucidate the mechanism of action of topoisomerase poisons.
Main Methods:
- Literature review of topoisomerase research.
- Analysis of biochemical data on topoisomerase-inhibitor interactions.
- Examination of clinical development of novel topoisomerase-targeting agents.
Main Results:
- Eukaryotic type IB topoisomerases (Top1) are targeted by camptothecins and novel noncamptothecins (e.g., indenoisoquinolines).
- Human type IIA topoisomerases (Top2alpha, Top2beta) are targeted by etoposide, anthracyclines, and mitoxantrone.
- Bacterial type II topoisomerases are targeted by quinolones and aminocoumarin antibiotics.
Conclusions:
- Topoisomerase poisons function by interfacial inhibition, stabilizing the covalent topoisomerase-cleavage complex.
- Understanding these mechanisms is key to developing new antimicrobial and anticancer therapies.
- Targeting topoisomerases remains a vital strategy in drug discovery.
Related Concept Videos
DNA Topoisomerases
Types and Mechanism of action
Topoisomerases are divided into two main types. Type I...
Inhibitors of Bacterial DNA Synthesis
Treatment Resistant Cancers
Drugs that Destabilize Microtubules
Drug Toxicity: Dose-Dependent Reactions
DNA Helicases

